Has Jupiter Life Lin declared dividend?

Jupiter Life Line Hospitals Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of August 2, 2024. While the 1-year total return is 25.66%, the 6-month return is -5.44%, and there have been no returns over longer periods.

Jupiter Life Line Hospitals Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 0.07%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -5.44%, the dividend return was 0%, resulting in a total return of -5.44%.<BR><BR>For the 1-year period, the price return was 25.58%, the dividend return was 0.08%, leading to a total return of 25.66%.<BR><BR>Over the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, there were no price or dividend returns, leading to a total return of 0.0%.<BR><BR>For the 4-year period, there were again no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, there were no price or dividend returns, leading to a total return of 0.0%.<BR><BR>Overall, while Jupiter Life Line Hospitals Ltd has declared a dividend, the total returns over various periods show mixed results, with significant returns in the 1-year period but negative returns in the 6-month period. The lack of returns in longer periods indicates potential volatility or stagnation in performance.

Is Jupiter Life Lin overvalued or undervalued?

As of June 11, 2025, Jupiter Life Lin is considered overvalued with a valuation grade of expensive, reflected in its high PE ratio of 51.71 and premium compared to peers, despite a strong 24.33% return over the past year.

As of 11 June 2025, Jupiter Life Lin's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its valuation outlook. The company is currently considered overvalued. Key financial ratios include a PE ratio of 51.71, an EV to EBITDA of 33.35, and a Price to Book Value of 7.37, all of which suggest a high valuation relative to its earnings and book value.<BR><BR>In comparison to its peers, Jupiter Life Lin's PE ratio is significantly higher than that of Narayana Hrudaya at 47.19 and Apollo Hospitals at 68.89, both of which are also in the expensive category. This indicates that Jupiter Life Lin is trading at a premium compared to its peers, which raises concerns about its valuation. Additionally, while the stock has outperformed the Sensex over the past year with a return of 24.33% compared to the Sensex's 7.92%, the overall high valuation metrics suggest that investors should exercise caution.

Who are the peers of the Jupiter Life Lin?

Jupiter Life Lin's peers include Global Health, Aster DM Health, Krishna Institute, Rainbow Child, Dr. Agarwal's Health, Health.Global, Kovai Medical, Yatharth Hospital, and Indraprastha Medical. Key insights show excellent management risk for several peers, average growth for Jupiter Life Lin, and Indraprastha Medical leading in 1-year returns at 99.54%.

Peers: The peers of Jupiter Life Lin are Global Health, Aster DM Health., Krishna Institu., Rainbow Child., Dr Agarwal's Hea, Health.Global, Kovai Medical, Yatharth Hospit., and Indrapr.Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Global Health, Krishna Institu., Dr Agarwal's Hea, Kovai Medical, Yatharth Hospit., Indrapr.Medical, and the rest. Average management risk is found at Aster DM Health. and Yatharth Hospit., while Below Average management risk is noted at Health.Global. Growth is rated as Good for Dr Agarwal's Hea, while Average growth is seen at Jupiter Life Lin and Global Health, and Below Average growth is noted at Aster DM Health., Krishna Institu., Rainbow Child., and Kovai Medical. Excellent capital structure is attributed to Global Health, Krishna Institu., Jupiter Life Lin, Yatharth Hospit., and Indrapr.Medical, while Below Average capital structure is found at Aster DM Health. and Health.Global.<BR><BR>Return Snapshot: Indrapr.Medical has the highest 1-year return at 99.54%, while Dr Agarwal's Hea has no available data for 1-year return, and Jupiter Life Lin's 1-year return is 11.28%. Additionally, Health.Global and Kovai Medical have negative six-month returns.

Who are in the management team of Jupiter Life Lin?

As of March 2023, the management team of Jupiter Life Lin includes Ajay Pratap Thakker (Chairman & Managing Director), Ankit Ajay Thakker (Executive Director & CEO), and several non-executive and independent directors, along with Suma Upparatti as Company Secretary & Compliance Officer. This team is responsible for the company's governance and strategic direction.

As of March 2023, the management team of Jupiter Life Lin consists of the following individuals:<BR><BR>1. **Ajay Pratap Thakker** - Chairman & Managing Director<BR>2. **Ankit Ajay Thakker** - Executive Director & CEO<BR>3. **Bhaskar Prataprai Shah** - Non Executive Director<BR>4. **Vadapatra Sayee Raghavan** - Non Executive Director<BR>5. **Darshan Hiralal Vora** - Independent Director<BR>6. **Jasmin A Patel** - Independent Director<BR>7. **Urmi Popat** - Independent Director<BR>8. **Satish Utekar** - Independent Director<BR>9. **Suma Upparatti** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Jupiter Life Lin do?

Jupiter Life Line Hospitals Ltd, a mid-cap company established in 2002 in Mumbai, operates in the hospital industry, reporting net sales of ₹3,267 Cr and a net profit of ₹449 Cr for March 2025. Key metrics include a P/E ratio of 51.00 and a market cap of ₹9,727 Cr.

Overview: <BR>Jupiter Life Line Hospitals Ltd operates in the hospital industry and is categorized as a mid-cap company.<BR><BR>History: <BR>Jupiter Life Line Hospitals Limited was incorporated in 2002 in Mumbai, Maharashtra, and commenced its business operations in December of the same year. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Net Sales: 3,267 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 449 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 9,727 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 51.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.13% <BR>Debt Equity: -0.15 <BR>Return on Equity: 14.26% <BR>Price to Book: 7.18 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Jupiter Life Lin?

The top shareholders of Jupiter Life Lin include promoters, with Ajay P Thakker holding 20.74%, and institutional investors, including mutual funds at 11.09% and foreign institutional investors at 10.03%. Individual investors collectively own 24.54%, with SBI Healthcare Opportunities Fund as the largest public shareholder at 7.29%.

The top shareholders of Jupiter Life Lin include a mix of promoters, institutional investors, and individual shareholders. The majority shareholders are the promoters, with Ajay P Thakker holding the highest individual stake at 20.74%. <BR><BR>In terms of institutional holdings, mutual funds collectively hold 11.09% through 15 different schemes, while foreign institutional investors (FIIs) account for 10.03% with 75 different FIIs involved. The highest public shareholder is the SBI Healthcare Opportunities Fund, which holds 7.29%. Additionally, individual investors collectively hold 24.54% of the company's shares.

How big is Jupiter Life Lin?

As of 24th July, Jupiter Life Line Hospitals Ltd has a market capitalization of 9,527.00 Cr, with recent Net Sales of 1,258.47 Cr and a Net Profit of 193.38 Cr. Shareholder's Funds are 1,356.24 Cr and Total Assets are 1,904.89 Cr.

As of 24th July, Jupiter Life Line Hospitals Ltd has a market capitalization of 9,527.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,258.47 Cr and a Net Profit of 193.38 Cr.<BR><BR>For the latest annual period ending in March 2025, the Shareholder's Funds amounted to 1,356.24 Cr, while the Total Assets were reported at 1,904.89 Cr.

When is the next results date for Jupiter Life Lin?

Jupiter Life Lin will announce its results on 07 November 2025.

Jupiter Life Lin will declare its results on 07 November 2025.

Are Jupiter Life Lin latest results good or bad?

Jupiter Life Line Hospitals' latest results show strong revenue growth and a net profit increase, but a decline in profit margin due to rising interest expenses raises concerns about long-term profitability. Investors should consider both the positive trends and the potential risks.

Jupiter Life Line Hospitals' latest results present a mixed picture. On the positive side, the company reported a net profit of ₹57.35 crores for Q2 FY26, reflecting a strong sequential growth of 30.67%. Revenue also showed healthy momentum, reaching ₹393.63 crores, which is an 11.53% increase from the previous quarter and a 17.48% increase year-on-year.<BR><BR>The operating margin improved to 23.44%, indicating better operational efficiency. However, there are notable concerns as well. The profit after tax margin decreased to 14.60% from 15.47% a year earlier, despite the revenue growth. This decline is primarily attributed to a significant rise in interest expenses, which surged to ₹7.84 crores, nearly doubling from the same quarter last year.<BR><BR>In summary, while the revenue and profit figures show positive growth trends, the rising interest costs and margin compression raise red flags about the company's profitability sustainability. Investors should weigh these factors when assessing the overall performance.

How has been the historical performance of Jupiter Life Lin?

Jupiter Life Lin experienced significant growth from March 2023 to March 2025, with net sales rising from 892.54 Cr to 1,302.40 Cr and profit after tax increasing from 72.91 Cr to 193.75 Cr, alongside a substantial rise in total assets. Overall, the company demonstrated robust improvements in sales, profitability, and asset base during this period.

Answer:<BR>The historical performance of Jupiter Life Lin shows significant growth across various financial metrics from March 2023 to March 2025.<BR><BR>Breakdown:<BR>Jupiter Life Lin's net sales increased from 892.54 Cr in March 2023 to 1,302.40 Cr in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 892.54 Cr to 1,302.40 Cr over the same period. Total expenditure, excluding depreciation, also grew from 691.22 Cr to 1,002.29 Cr, indicating increased operational costs. Operating profit (PBDIT) saw a notable increase from 211.74 Cr in March 2023 to 328.46 Cr in March 2025, with the operating profit margin slightly improving to 23.04% in March 2025. Profit before tax rose from 128.71 Cr to 260.68 Cr, while profit after tax increased from 72.91 Cr to 193.75 Cr, showcasing enhanced profitability. The consolidated net profit also grew from 72.91 Cr to 193.20 Cr. On the balance sheet, total assets surged from 985.53 Cr in March 2023 to 1,904.89 Cr in March 2025, with total liabilities increasing from 985.53 Cr to 1,904.89 Cr. Cash flow from operating activities remained stable, with a net cash inflow of 166.00 Cr in March 2024, up from 31.00 Cr in March 2023. Overall, Jupiter Life Lin demonstrated robust growth in sales, profits, and asset base over the observed period.

How has been the historical performance of Jupiter Life Lin?

Jupiter Life Lin has demonstrated significant growth over the past three years, with net sales increasing from 892.54 Cr to 1,302.40 Cr, and profit after tax rising from 72.91 Cr to 193.75 Cr. Key financial metrics, including operating profit and earnings per share, also showed substantial improvement during this period.

Answer:<BR>The historical performance of Jupiter Life Lin shows significant growth across various financial metrics over the past three years.<BR><BR>Breakdown:<BR>Jupiter Life Lin's net sales have increased from 892.54 Cr in March 2023 to 1,302.40 Cr in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 892.54 Cr to 1,302.40 Cr during the same period. Total expenditure, excluding depreciation, also grew from 691.22 Cr to 1,002.29 Cr, indicating increased operational costs. Operating profit (PBDIT) rose from 211.74 Cr in March 2023 to 328.46 Cr in March 2025, while profit before tax improved from 128.71 Cr to 260.68 Cr. The profit after tax also saw a notable increase, growing from 72.91 Cr to 193.75 Cr. The earnings per share (EPS) increased significantly from 12.9 to 29.46, demonstrating enhanced profitability per share. On the balance sheet, total assets expanded from 985.53 Cr in March 2023 to 1,904.89 Cr in March 2025, with total liabilities also rising from 985.53 Cr to 1,904.89 Cr. Cash flow from operating activities remained relatively stable, while net cash inflow surged from 31 Cr in March 2023 to 166 Cr in March 2024, indicating improved liquidity. Overall, Jupiter Life Lin has shown robust growth in sales, profits, and asset base over the past three years.

Is Jupiter Life Lin technically bullish or bearish?

As of November 14, 2025, the trend is mildly bullish due to a bullish MACD and moving averages, but mixed signals from Bollinger Bands and RSI suggest caution.

As of 14 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and mildly bullish moving averages on the daily timeframe. However, the weekly Bollinger Bands indicate a bearish sentiment, and the RSI shows no signals on both weekly and monthly timeframes. The Dow Theory reflects a mildly bullish position on the weekly chart, while the monthly shows no trend. Overall, the strength of the bullish stance is tempered by mixed signals from other indicators.

Should I buy, sell or hold Jupiter Life Lin?

Which are the latest news on Jupiter Life Lin?

Why is Jupiter Life Lin falling/rising?

As of 17-Dec, Jupiter Life Line Hospitals Ltd is experiencing a slight decline in its stock price, currently at 1,409.00, reflecting a bearish trend with underperformance compared to the Sensex and high valuation metrics. The stock has fallen for three consecutive days and is trading below all major moving averages, indicating ongoing negative sentiment.

As of 17-Dec, Jupiter Life Line Hospitals Ltd is experiencing a slight decline in its stock price, currently at 1,409.00, reflecting a change of -0.55 (-0.04%). The stock has been on a downward trend, having fallen for the last three consecutive days, resulting in a total decline of -0.76% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>In terms of performance relative to the market, Jupiter Life Line has underperformed compared to the Sensex over various time frames, including a -10.01% return over the past year, while the Sensex has gained 4.80%. This underperformance is compounded by a year-to-date decline of -9.17% against the Sensex's increase of 8.22%. <BR><BR>Despite a rise in investor participation, with delivery volume increasing by 11.41% against the 5-day average, the overall sentiment remains negative due to the company's flat results reported on September 25 and its high valuation metrics, such as a Price to Book Value of 6.4. The stock's performance has also been hindered by a high PEG ratio of 5.6, suggesting that it may be overvalued relative to its earnings growth.<BR><BR>Overall, the combination of recent price declines, poor performance relative to benchmarks, and high valuation metrics contribute to the stock's current downward trajectory.